Compare AbbVie Inc (ABBV) vs Aterian Inc (ATER) Price & Performance

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

Aterian (ATER) trades at $0.4934, up 7.03% in the last 24 hours, with a bearish technical signal overall. The company reported revenue of $68.98 million in 2025 but a net loss of $18.98 million, showing negative margins despite recent earnings beats. Recent news highlights a pending asset sale vote that could return $0.85–$1.14 per share to stockholders, creating near-term event-driven volatility.

The outlook hinges on the asset sale outcome, offering potential shareholder returns but also signaling business contraction. Risks include persistent cash burn, declining revenue, and high negative equity. Analysts are split 50/50 buy/hold, reflecting uncertainty amid restructuring efforts.